Clinical Research Directory
Browse clinical research sites, groups, and studies.
Graves' Disease Remission Study: MycoMeth Combo
Sponsor: The First Affiliated Hospital of Xiamen University
Summary
A randomized study to evaluate the efficacy and safety of combining mycophenolate mofetil with methimazole in patients with newly diagnosed Graves' disease.
Official title: The Efficacy and Safety of Combining Mycophenolate Mofetil With Methimazole on Remission of Newly Diagnosis Graves' Disease (3M-RGD Trial): an Open-label, Randomized Trial
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
205
Start Date
2023-10-16
Completion Date
2026-10-08
Last Updated
2024-02-28
Healthy Volunteers
No
Conditions
Interventions
Mycophenolate Mofetil, Oral, 250 Mg
Mycophenolate Mofetil, Oral, 500Mg twice daily for 12 months, combined with methimazole standard therapy
methimazole, oral, 10mg
Methimazole 15-30mg daily initially then titrate to maintenance dose.
Locations (1)
Xiao Fangsen
Xiamen, Fujian, China